Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2009-2.4.5-1 | Award Amount: 7.81M | Year: 2010

Non-alcoholic fatty liver disease (NAFLD) has become one of the top concerns for the practising hepatogastroenterologist due to the obesity epidemic and its potential to progress to advanced liver disease which significantly impacts on overall and liver-related mortality. The aim of the FLIP (Fatty Liver: Inhibition of Progression) project is to understand and prevent the progression of liver disease in NAFLD. FLIP is a consortium of basic scientists and practising clinical hepatologists with an established track record and focus on research into the underlying mechanisms and management of patients with NAFLD. Therefore FLIP provides a unique opportunity to assemble the largest European cohort of patients with histologically diagnosed NAFLD with clinical and epidemiological data and with biobanks of DNA, frozen liver tissue and serum. These will be used in a wide range of collaborative inter-disciplinary research projects aimed at addressing key unanswered questions related to the mechanisms and consequences of liver injury in NAFLD and the development of novel preventive and therapeutic strategies. The main outcomes of FLIP will be new insights in the progression of liver disease in NAFLD in terms of initiating mechanisms and patients at risk, innovative diagnostic methods particularly adapted for large-scale screening and prognostic evaluation, improved implementation of lifestyle changes, collaboration with leading biotechnological or pharmaceutical companies in order to translate to the market diagnostic tests or newly identified molecular targets for pharmacological therapy. By disseminating the projects results, FLIP will further help the European Community to suggest guidelines on the management of this emerging liver disease. The long-term goal is to lay the foundations for the future of NAFLD research in Europe by creating a Collaborative Research Network on NAFLD that will continue the work initiated by the FLIP consortium.


Barbero-Becerra V.J.,Fondazione Italiana Fegato ONLUS | Barbero-Becerra V.J.,Obesity and Digestive Disease Unit | Santiago-Hernandez J.J.,Obesity and Digestive Disease Unit | Villegas-Lopez F.A.,Obesity and Digestive Disease Unit | And 3 more authors.
Current Medicinal Chemistry | Year: 2012

Metformin is an antidiabetic drug used widely in clinical practice. Its main clinical effect is to reduce blood glucose levels by improving insulin resistance. Nonalcoholic fatty liver disease is characterized by chronic liver damage and can develop into liver cirrhosis. Nonalcoholic fatty liver disease is associated with obesity and contributes to insulin resistance, and metformin is used to treat individuals with these conditions. The mechanisms underlying the clinical effects of metformin in treating nonalcoholic fatty liver disease are unclear. This article summarizes the literature on the mechanisms associated with liver glucose metabolism and the beneficial effects of metformin on this common liver disease. © 2012 Bentham Science Publishers.


PubMed | Fondazione Italiana Fegato ONLUS
Type: Journal Article | Journal: Current medicinal chemistry | Year: 2012

Metformin is an antidiabetic drug used widely in clinical practice. Its main clinical effect is to reduce blood glucose levels by improving insulin resistance. Nonalcoholic fatty liver disease is characterized by chronic liver damage and can develop into liver cirrhosis. Nonalcoholic fatty liver disease is associated with obesity and contributes to insulin resistance, and metformin is used to treat individuals with these conditions. The mechanisms underlying the clinical effects of metformin in treating nonalcoholic fatty liver disease are unclear. This article summarizes the literature on the mechanisms associated with liver glucose metabolism and the beneficial effects of metformin on this common liver disease.


PubMed | Fondazione Italiana Fegato ONLUS
Type: Editorial | Journal: Expert review of gastroenterology & hepatology | Year: 2015

There is a fast growing body of evidence that shows several miRNAs are essential to the key features of cancer stem cells (CSC) in hepatocellular carcinoma. However, the function of the miRNAs in different hepatic CSCs and their role in multidrug resistance mechanisms, in particular in those related to the CSC marker ABCG2, is still poorly understood. This limitation is mainly due to the heterogeneity of hepatocellular carcinoma tissues, different CSC markers and high number of deregulated miRNAs, both in primary tumor sites as well as in the circulation. The identification of CSC-related miRNAs and the modulation of hepatocellular carcinoma multidrug resistance would provide a systemic approach in the management of the disease.

Loading Fondazione Italiana Fegato ONLUS collaborators
Loading Fondazione Italiana Fegato ONLUS collaborators